Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001004156 | SCV001162921 | pathogenic | Cobalamin C disease | criteria provided, single submitter | clinical testing | ||
Invitae | RCV001004156 | SCV002247292 | pathogenic | Cobalamin C disease | 2023-12-19 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Thr210Aspfs*35) in the MMACHC gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 73 amino acid(s) of the MMACHC protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with clinical features of methylmalonic aciduria and homocystinuria (PMID: 19573432, 29581464, 29731766). This variant is also known as c.625_626insT and c.625insT. ClinVar contains an entry for this variant (Variation ID: 813353). This variant disrupts a region of the MMACHC protein in which other variant(s) (p.Tyr222*) have been determined to be pathogenic (PMID: 16311595, 19767224, 30157807). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV001004156 | SCV004178214 | pathogenic | Cobalamin C disease | 2023-04-11 | criteria provided, single submitter | clinical testing |